Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: A systematic review and meta-analysis.

BACKGROUND:

Biological therapy is effective for the treatment of psoriasis and psoriatic arthritis; however, adverse effects related to immunosuppression, such as viral infections, have been reported. Amongst these infections, herpes zoster (HZ) is common.

OBJECTIVE:

To evaluate the risk of HZ in psoriasis and psoriatic arthritis patients treated with biological therapy.

DATA SOURCES:

A comprehensive literature search of PubMed, Embase, and Web of Science was performed using certain keywords until October 9, 2020. Nine studies were included after a detailed assessment.

STUDY ELIGIBILITY CRITERIA:

The eligibility criteria included randomized controlled trials (RCTs) and observational studies of patients with psoriasis or psoriatic arthritis treated with biological therapies; compared with non-biological therapies, non-biological systemic therapies, or controls; with the incidence of HZ reported in case and control groups. The Cochrane risk of bias tool and Newcastle-Ottawa scale were used to assess the quality of the RCTs and observational studies, respectively. Data were extracted from 9 eligible studies and then analyzed using Stata software (Version 12.0).

RESULTS:

The risk of HZ in biological therapies was higher than that in non-biological (odds ratios [OR]: 1.48; 95% confidence interval [CI]: 1.18-1.86; I2 = 0%) and non-biological systemic (OR: 1.32; 95% CI.: 1.02-1.71; I2 = 0%) therapies. Furthermore, the risk of HZ associated with tumor necrosis factor-α inhibitors increased significantly (OR: 1.50; 95% CI.: 1.11-2.02; I2 = 0%). Notably, infliximab (OR: 2.43; 95% CI.: 1.31-4.50; I2 = 0%) and etanercept (OR: 1.65; 95% CI.: 1.07-2.56; I2 = 0%) increased the risk of HZ, while adalimumab (OR: 1.21; 95% CI.: 0.64-2.30; I2 = 0%), ustekinumab (OR: 2.20; 95% CI.: 0.89-5.44; I2 = 0%), alefacept (OR: 1.46; 95% CI.: 0.20-10.47; I2 = 0%), and efalizumab (OR: 1.58; 95% CI.: 0.22-11.34; I2 = 0%) did not.

LIMITATIONS:

Few RCTs have reported HZ incidents; thus, our results require confirmation via large-scale RCTs.

CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS:

Biological therapies, especially tumor necrosis factor-α inhibitors, may lead to the risk of HZ in psoriasis and psoriatic arthritis patients. Amongst these agents, infliximab and etanercept have been shown to significantly increase the risk of HZ. Additionally, younger age and female sex may be risk factors.

SYSTEMATIC REVIEW REGISTRATION NUMBER:

INPLASY202110027.